Ferric Carboxymaltose

Ferric Carboxymaltose (FCM) is a scientifically advanced intravenous iron replacement therapy developed for effective management of iron deficiency anemia. Unlike conventional iron salts, it is a carbohydrate-based iron (III) complex, offering superior stability, safety, and patient tolerability.

The formulation is colourless, odourless, and non-hygroscopic, eliminating the metallic taste and moisture sensitivity commonly associated with traditional iron preparations.

As a leading API manufacturer, WBCIL follows strict cGMP and ISO quality systems, backed by manufacturing expertise since 1962, ensuring consistent potency, purity, and safety.

Key Therapeutic Advantages:

• High-dose iron delivery with rapid correction of iron deficiency
• Controlled iron release minimizing adverse reactions
• Fewer infusions compared to conventional IV iron therapies
• Improved patient compliance and clinical outcomes

WBCIL Product Highlights:

• Two patents held by WBCIL on Ferric Carboxymaltose
• Two eminent scientific journals have published studies on WBCIL’s FCM
• Minimal hypersensitivity reactions reported
• Sameness study completed with the innovator product
• Compliant with Indian Pharmacopoeia (IP)
• Supported by COPP and Written Confirmation (WC)

Applications in Medical Fields:

• Iron Deficiency Anemia Treatment
• Chronic Kidney Disease
• Rapid Iron Replenishment
• Postpartum Anemia
• Chronic Heart Failure
• Inflammatory Bowel Disease